U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07021209) titled 'Clinical Study of GT719 Injection for Recurrent/Refractory Antibody Mediated Systemic Immune Diseases' on May 29.

Brief Summary: This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune disorders.

Study Start Date: Jan. 14

Study Type: INTERVENTIONAL

Condition: Neurological Disorder

Intervention: BIOLOGICAL: GT719 Injection

GT719 Injection

Recruitment Status: RECRUITING

Sponsor:...